Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
Holding NVCR?
Track your performance easily
NVCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.70 - $34.13
Previous CloseN/A
Volume205.01K
Average Volume (3M)1.04M
Market Cap
$2.85B
Enterprise Value$1.40B
Total Cash (Recent Filing)$219.63M
Total Debt (Recent Filing)$96.77M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Feb 27, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding108,201,430
10 Day Avg. Volume1,016,986
30 Day Avg. Volume1,044,684
Standard Deviation0.22
R-Squared0.02
Alpha-0.00238
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.93
Price to Cash Flow (P/CF)68.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit3.68
Enterprise Value/Ebitda-13.55
Forecast
1Y Price Target
$38.00Price Target Upside48.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
NovoCure News
Bulls Say, Bears Say
Bulls Say
Clinical Study SuccessNVCR announced positive topline results from the Phase III PANOVA-3 study evaluating Tumor Treating Fields (TTFields) in unresectable, locally advanced pancreatic adenocarcinoma.
International ExpansionOngoing international expansion, and the continued global rollout of Head Flexible Electrode (HFE) transducer arrays, will continue to contribute to sustained sales growth.
Market OpportunityThere is a positive view on NVCR relative to its current valuation, considering the floor value of Optune in glioblastoma multiforme and potential revenue upside from additional TTFields indications.
Bears Say
Prescription TrendsPrescriptions for Optune Gio shrunk overall with 1,520 received in the quarter compared to 1,586 previously, a 4% decrease.
Revenue PerformanceRevenue in Greater China was below estimates and represented only about half of historical quarterly revenue.
Strategic RisksRisks include safety signals, lower-than-expected efficacy, greater commercial competition, and regulatory concerns related to NovoCure's assets.
---
Ownership Overview
1.40% Insiders
35.92% Mutual Funds
0.05% Other Institutional Investors
46.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVCR FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $11.70 and its highest was $34.13 in the past 12 months.
What is NovoCure Ltd’s market cap?
NovoCure Ltd’s market cap is $2.85B.
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Feb 27, 2025 which is in 28 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Oct 30, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.334 by $0.054.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -0.34.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 108,201,430 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.334. Following the earnings report the stock price went up 0.592%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Among the largest hedge funds holding NovoCure Ltd’s share is Coatue Management, LLC. It holds NovoCure Ltd’s shares valued at 10M.
---
NovoCure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (48.90% Upside)
$38.00 (48.90% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 11.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 12.4%
Last 30 Days ▲ 12.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.00%
12-Months-Change
Fundamentals
Return on Equity
-39.70%
Trailing 12-Months
Asset Growth
6.60%
Trailing 12-Months
Company Description
NovoCure Ltd
NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
---
NVCR Company Deck
---
NVCR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected significant achievements, including the approval of Optune Lua for non-small cell lung cancer and strong revenue and patient growth. However, challenges such as regulatory delays in Europe and anticipated gross margin pressures were noted. Overall, the positive highlights, particularly the FDA approval and revenue growth, outweigh the lowlights.Read More>---
NVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
---
NVCR Stock 12 Month Forecast
Average Price Target
$38.00
▲(48.90% Upside)
Technical Analysis
Insulet
―
Integra Lifesciences
―
QuidelOrtho
―
Zimmer Biomet Holdings
―
Tandem Diabetes Care
―
Best Analysts Covering NVCR
1 Year
1 Year Success Rate
13/18 ratings generated profit
1 Year Average Return
+30.83%
reiterated a buy rating 17 days ago
Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +30.83% per trade.
---